Clinical trials: Cervical Intraepithelial
Cervical Intraepithelial Neoplasia
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects
The purpose of this prospective, multi-centre, PMS cohort study was to monitor the safety of Cervarix, which is the first HPV vaccine licensed for use in China, to help prevent cervical cancer caused by HPV types 16 and 18.
- Trial name
- NCT03438006
- Testing
- Safety data collection (following routine vaccination)
- Where
- 7 sites in China
- Volunteers
- 3,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- TG-003 (NCT00596258)
- Testing
- A-007
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tigris Pharmaceuticals
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16…
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Cervical Intraepithelial Neoplasia
- Trial name
- NCT02733068
- Testing
- HPV-16/18 vaccine
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Cervical Intraepithelial Neoplasia 3
Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3
This study is to determine maximum tolerable dose (MTD) of GX 188E by defining the safety profile the safety and maximum tolerated dose of GX-188E administered by electroporation in Cervical Intraepithelial Neoplasia grade 3 (CIN…
- Trial name
- CIN3 (NCT01634503)
- Testing
- GX-188E administered by electroporation
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Genexine, Inc.
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- NCT00285207
- Testing
- A007
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tigris Pharmaceuticals
Cervical Intraepithelial Neoplasia, Cervical Cancer
DNA Methylation Biomarkers for Cervical Cancer Screening
The purpose of this prospective study is to evaluate whether DNA methylation can be applied in cervical cancer screening.
- Trial name
- NCT02605941
- Where
- Taiwan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- iStat Biomedical CO., Ltd.
Cervical Intraepithelial Neoplasia, Papillomavirus Infection
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all…
- Trial name
- NCT00316706
- Testing
- GSK Biologicals' HPV-16/18 Vaccine (Cervarix™), Havrix™
- Where
- 28 sites in Colombia, Germany and 3 more
- Volunteers
- 1,245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
High-grade Squamous Intraepithelial Lesion (HSIL)
NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and tolerability of HPV-16 and HPV-18-targeted DNA plasmid vaccine (NWRD08) in patients HPV-16 and/or HPV-18 related cervical HSIL.
- Trial name
- NCT06276101
- Testing
- NWRD08 administered by electroporation
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
High-grade Squamous Intraepithelial Lesion (HSIL)
Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically…
- Trial name
- NCT07175662
- Testing
- NWRD08 administered by electroporation
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Newish Biotech (Wuxi) Co., Ltd.
Cervical Intraepithelial Neoplasia
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
- Trial name
- NCT05496231
- Testing
- HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation
- Where
- 68 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Intraepithelial Neoplasia
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
- Trial name
- NCT02596243
- Testing
- GX-188E
- Where
- 16 sites in Estonia, South Korea and 1 more
- Volunteers
- 134 people
- Sponsor
- Genexine, Inc.
High-grade Squamous Intraepithelial Lesions (HSIL)
A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL
This study is intented to evaluate the safety, and tolerability and preliminary efficacy of Instantaneous CRISPR/Cas9 Gene Editing Therapy (BD114 virus-like particle, also BD114) for the treatment of high-grade squamous…
- Trial name
- NCT07170254
- Testing
- BD114VLP, or BD114
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
CIN - Cervical Intraepithelial Neoplasia, CIN 1
A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.
The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis.
- Conditions
- CIN - Cervical Intraepithelial Neoplasia, CIN 1, CIN 2, HPV
- Trial name
- NCT06979180
- Testing
- Papillex®
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Papillex Inc.
Cervical Cancer, Cervical Intraepithelial Neoplasia II
Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer
The purpose of this study is to determine whether Insulin-like Growth Factor II is elevated sufficiently to detect Cervical Intraepithelial Neoplasia II (CIN II), Cervical Intraepithelial Neoplasia III (CIN III), and cervical…
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia II, Cervical Intraepithelial Neoplasia III
- Trial name
- NCT01371695
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Onconix, Inc
I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS)
Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer
This study compares how effective is the molecular screening (a blood test) using Pap smear as reference, that is, a comparison of these tests abilities to detect precursor lesions and cervical cancer among women of an open…
- Conditions
- I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS), III) Cervical Intraepithelial Neoplasia (CIN), CIN-1, CIN-2, CIN-3, IV) Low-grade Squamous Intraepithelial Lesion (LSIL)
- Trial name
- NCT07480902
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Cervical Intraepithelial Neoplasia
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
Cervical cancer is associated with Human Papilloma Virus. About 57% of cervical cancer is the result of infection by Human Papilloma Virus strain 16 (HPV-16). HPV is a very common virus that can affect the cells of the cervix.
- Trial name
- ADXS11-001 (NCT01116245)
- Testing
- ADXS11-001 (Lm-LLO-E7)
- Where
- 15 sites in United States
- Volunteers
- 81 people
- Sponsor
- Advaxis, Inc.
Cervical Intraepithelial Neoplasia
A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
This randomized, double-blind, placebo-controlled, parallel arm study will assess the safety and the efficacy of RO5217790 on histologic resolution in participants with high grade CIN associated with HR-HPV infection.
- Trial name
- NCT01022346
- Testing
- RO5217790
- Where
- 66 sites in United States, Belgium and 4 more
- Volunteers
- 206 people
- Sponsor
- Hoffmann-La Roche
Human Papillomavirus (HPV), Cervical Intraepithelial Neoplasia
Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer
The purpose of this study is to validate Automated Visual Evaluation (AVE), specifically the CINFinder version developed by DL Analytics, a point-of-care screening and triage diagnostic tool for cervical cancer based on the…
- Conditions
- Human Papillomavirus (HPV), Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms, Cervical Cancers
- Trial name
- OPTICS (NCT06815939)
- Testing
- HPV Test, EVA System, Visual Inspection with Acetic Acid (VIA)
- Where
- El Salvador
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- DL Analytics